Elevidys Sales Surge in Sarepta Q2 2025 Despite Safety Concerns

Sarepta Therapeutics reported strong Q2 2025 results, with Elevidys sales driving a 42% year-over-year revenue increase to approximately $282 million35.

The FDA temporarily paused shipments of Elevidys for non-ambulatory patients over safety concerns, but this restriction was lifted for ambulatory patients in late July 202515.

Sarepta faced regulatory scrutiny and market pressure following the pause, partly due to deaths linked to its investigational gene therapy assets (not Elevidys), but the company resumed Elevidys deliveries and saw improved investor confidence after the FDA’s decision14.

Despite recent safety controversies, Sarepta outperformed earnings and sales estimates for the quarter, with its share price rebounding 5% in after-hours trading after the earnings release1.

Sarepta has restructured and paused development of several gene therapy programs amid ongoing safety reviews, but continues its commercial push for Elevidys within the FDA’s allowed indications4.

Sources:

1. https://www.chartmill.com/news/SRPT/Chartmill-32569-Sarepta-Therapeutics-Inc-NASDAQSRPT-Surpasses-Q2-2025-Estimates-with-Strong-ELEVIDYS-Performance

3. https://www.zacks.com/stock/news/2678493/sarepta-soars-on-q2-earnings-sales-beat-resumes-elevidys-deliveries

4. https://www.fiercepharma.com/pharma/sarepta-stands-ground-elevidys-sales-after-fda-requests-gene-therapy-be-pulled-market

5. https://www.moomoo.com/community/feed/q2-2025-earnings-overview-114983800799238